Mitoxantrone, vinblastine and CCNU: Long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease

Leukemia and Lymphoma

Volumn 47, Issue 4, 2006, Pages 641-656

  Alexandrescu, Doru T ^a   Karri, Sirisha ^a   Wiernik, Peter ^a   Dutcher, Janice P ^a  

^a OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

Advanced stage; CCNU; Hodgkin's disease; Mitoxantrone; MVC; Poor prognosis; Salvage therapy; Vinblastine

Indexed keywords

ANTIEMETIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LOMUSTINE; MELPHALAN; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; STREPTOZOCIN; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFECTION; LONG TERM CARE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; MYELOID LEUKEMIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOMUSTINE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE;

EID: 33646758228     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500376241     Document Type: Article

References (54)

1. Balzarotti, M and Wiernik, P and Santoro, A.(2003) Diagnosis and treatment of Hodgkin's disease. In Neoplastic Diseases of the Blood 4th edn. (pp. 862-892). New York NY: Cambridge University Press.
2. Bonadonna, G and Valagussa, P and Santoro, A. (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results Ann Intern Med, 104, pp. 739-746.
3. Santoro, A and Bonadonna, G and Valagussa, P and Zucali, R and Viviani, S and Villani, F and (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy J Clin Oncol, 5, pp. 27-37.
4. Wiernik, P and Schiffer, C. (1988) Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB) J Cancer Res Clin Oncol, 114, pp. 105-107.
5. Longo, D and Duffey, P and DeVita, V, Jr and et al. (1991) Treatment of advanced-stage Hodgkin's disease: Alternating noncrossresistant MOPP/ CABS is not superior to MOPP J Clin Oncol, 9, pp. 1409-1420.
6. Levi, J and Wiernik, P and Diggs, C. (1977) Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin Med Pediatr Oncol, 3, pp. 33-40.
7. Benjamin, R and Chawla, S and Ewer, M and Carrasco, C and Mackay, B and Holmes, F. (1985) Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: An update Invest New Drugs, 3, pp. 117-121.
8. Dutcher, J and Wiernik, P and Einzig, A and Sparano, J and Frank, M and Friedenberg, W. (1993) Mitoxantrone, vinblastine and CCNU (MVC): A highly active regimen in poor prognosis Hodgkin's disease Blood, 82, pp. 143.
9. Dutcher, J and Wiernik, P. (1996) Mitoxantrone, Vinblastine and CCNU (MVC): A highly active regimen in poor prognosis Hodgkin's disease. Proceedings of the VI International Conference on Malignant Lymphoma, Lugano, 5-8 June 1996 Ann Oncol, 7, pp. 115.
10. Cooper, M and Spurr, C and Glidewell, O and (1975) The superiority of a nitrosourea (CCNU) containing four drug combination over MOPP in the treatment of stage III and IV Hodgkin's disease Blood, 46, pp. 1014-1019.
11. Wiernik, P and Dutcher, J and Einzig, A and Sparano, J and Frank, M and Friedenberg, W. (1998) Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): A highly active regimen for advanced and poor-prognosis Hodgkin's disease Cancer J Sci Am, 4, pp. 254-260.
12. Hansen, H and Selawry, O and Pajak, T and Spurr, C and Falkson, G and Brunner, K. (1981) The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study Cancer, 47, pp. 14-18.
13. Wiernik, P and Wang, S and Hu, X and Marino, P and Paietta, E. (2000) Age of onset evidence for anticipation in familial non-Hodgkin's lymphoma Br J Haematol, 108, pp. 72-79.
14. Ashigbi, M and Venkatraj, U and Agarwal, V and Bello, J and Wiernik, P. (1997) Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease Med Pediatr Oncol, 28, pp. 255-258.
15. Schmitz, N and Pfistner, B and Sextro, M and Sieber, M and Carella, A and Haenel, M and et al. (2002) German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial Lancet, 359, pp. 2065-2071.
16. Ferme, C and Mounier, N and Divine, M and Brice, P and Stamatoullas, A and Reman, O and et al. (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial J Clin Oncol, 20, pp. 467-475.
17. Yuen, A and Rosenberg, S and Hoppe, R and Halpern, J and Horning, S. (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease Blood, 89, pp. 814-822.
18. Levi, J and Wiernik, P and Diggs, C. (1977) Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin Med Pediatr Oncol, 3, pp. 33-40.
19. Sutcliffe, S and Wrigley, P and Stansfeld, A and Malpas, J. (1979) Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP) Cancer Chemother Pharmacol, 2, pp. 209-213.
20. Gassmann, W and Perenyi, L and Pralle, H and Graubner, M and Schmitz, N and Loffler, H. (1981) Results of treatment with ABVD in C-MOPP-resistant Hodgkin's disease Klin Wochenschr, 59, pp. 267-273.
21. Santoro, A and Bonfante, V and Bonadonna, G. (1982) Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease Ann Intern Med, 96, pp. 139-143.
22. Straus, D and Myers, J and Koziner, B and Lee, B and Clarkson, B. (1983) Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV) Cancer Chemother Pharmacol, 11, pp. 80-85.
23. Piga, A and Ambrosetti, A and Todeschini, G and Cetto, G and Perona, G and Cellerino, R. (1984) Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease Cancer Treat Rep, 68, pp. 947-951.
24. Santoro, A and Viviani, S and Valagussa, P and Bonfante, V and Bonadonna, G. (1986) CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease Semin Oncol, 13, pp. 23-26.
25. Pfreundschuh, M and Schoppe, W and Fuchs, R and Pfluger, K and Loeffler, M and Diehl, V. (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): A multicenter trial of the German Hodgkin Study Group Cancer Treat Rep, 71, pp. 1203-1207.
26. Cabanillas, F and Velasquez, W and McLaughlin, P and Jagannath, S and Hagemeister, F and Redman, J and et al. (1988) Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease Semin Hematol, 25, pp. 47-50.
27. Brusamolino, E and Orlandi, E and Canevari, A and Morra, E and Castelli, G and Alessandrino, E and et al. (1994) Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease Ann Oncol, 5, pp. 427-432.
28. Brice P, Bastion Y and Divine, M and Nedellec, G and Ferrant, A and Gabarre, J and et al. (1996) Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients Cancer, 78, pp. 1293-1299.
29. Andre, M and Henry-Amar, M and Pico, J and Blaise, D and Kuentz, M and Coiffier, B and et al. (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. Societe Francaise de Greffe de Moelle J Clin Oncol, 17, pp. 222-229.
30. Bonfante, V and Viviani, S and Devizzi, L and Russo, A and Di Nicola, M and Magni, M and et al. (2001) High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease Eur J Haematol Suppl, 64, pp. 51-55.
31. Zinzani, P and Tani, M and Molinari, A and Stefoni, V and Zuffa, E and Alinari, L and et al. (2002) Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients Haematologica, 87, pp. 816-821.
32. Cabanillas, F and Velasquez, W and McLaughlin, P and Jagannath, S and Hagemeister, F and Redman, J and et al. (1988) Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease Semin Hematol, 25, pp. 47-50.
33. Spinolo, J and Jagannath, S and Velasquez, W and Spitzer, G and Cabanillis, F and Hagemeister, F and et al. (1993) Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease Leuk Lymphoma, 9, pp. 71-77.
34. Chopra, R and McMillan, A and Linch, D and Yuklea, S and Taghipour, G and Pearce, R and et al. (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients Blood, 81, pp. 1137-1145.
35. Pfreundschuh M, and Rueffer, U and Lathan, B and Schmitz, N and Brosteanu O, and Hasenclever, D and et al. (1994) Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group J Clin Oncol, 12, pp. 580-586.
36. Reece, D and Barnett, M and Shepherd, J and Hogge, D and Klasa, R and Nantel, S and et al. (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV±P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy Blood, 86, pp. 451-456.
37. Bierman, P and Anderson, J and Freeman, M and Vose, J and Kessinger, A and Bishop, M and et al. (1996) High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy Ann Oncol, 7, pp. 151-156.
38. Sweetenham, J and Taghipour, G and Milligan, D and Blystad, A and Caballero, D and Fassas, A and et al. (1997) High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant, 20, pp. 745-752.
39. Majolino, I and Pearce, R and Taghipour, G and Goldstone, A. (1997) Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: A new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol, 15, pp. 509-517.
40. Lazarus, H and Rowlings, P and Zhang, M and Vose, J and Armitage, J and Bierman, P and et al. (1999) Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry J Clin Oncol, 17, pp. 534-545.
41. Sureda, A and Arranz, R and Iriondo, A and Carreras, E and Lahuerta, J and Garcia-Conde, J and et al. (2001) Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group J Clin Oncol, 19, pp. 1395-1404.
42. Anselmo, A and Cavalieri, E and Meloni, G and Cantonetti, M and Maurizi and Enrici, R and et al. (2002) Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease Haematologica, 87, pp. 507-511.
43. Stiff, P and Unger, J and Forman, S and McCall, A and LeBlanc, M and Nademanee, A and et al. (2003) Southwest Oncology Group. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial Biol Blood Marrow Transplant, 9, pp. 529-539.
44. Gutierrez-Delgado, F and Holmberg, L and Hooper, H and Petersdorf, S and Press, O and Maziarz, R and et al. (2003) Autologous stem cell transplantation for Hodgkin's disease: Busulfan, melphalan and thiotepa compared to a radiation-based regimen Bone Marrow Transplant, 32, pp. 279-285.
45. Qazilbash, M and Devetten, M and Abraham, J and Lynch, J and Beall, C and Auber, M and et al. (2003) High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model Acta Haematol, 110, pp. 173-178.
46. Constans, M and Sureda, A and Terol, M and Arranz, R and Caballero, M and Iriondo, A and et al. (2003) Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome Ann Oncol, 14, pp. 745-751.
47. Duggan, D and Petroni, G and Johnson, J and Glick, J and Fisher, R and Connors, J and et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial J Clin Oncol, 21, pp. 607-614.
48. Chisesi, T and Federico, M and Levis, A and Deliliers, G and Gobbi, P and Santini, G and et al. (2002) ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: Results of a randomised trial Ann Oncol, 13(Suppl 1), pp. 102-106.
49. Horning, S and Hoppe, R and Breslin, S and Bartlett, N and Brown, B and Rosenberg, S and et al. 2002 Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20, pp. 630-637.
50. Diehl, V and Franklin, J and Pfreundschuh, M and Lathan, B and Paulus, U and Hasenclever, D and et al. 2003 German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease N Engl J Med, 348, pp. 2386-2395.
51. Harrison, C and Gregory, W and Hudson, G and Devereux, S and Goldstone, A and Hancock, B and et al. (1999) High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML Br J Cancer, 81, pp. 476-483.
52. Elghetany, M. (1997) Hodgkin's disease coexisting with myelodysplastic syndrome prior to therapy: A case report and a review of the association of Hodgkin's disease with stem cell disorders Ann Hematol, 75, pp. 231-234.
53. Brusamolino, E and Anselmo, A and Klersy, C and Santoro, M and Orlandi, E and Pagnucco, G and et al. (1998) The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: A case-control study Haematologica, 83, pp. 812-823.
54. Cimino, G and Papa, G and Tura, S and Mazza, P and Rossi Ferrini, P and Bosi, A and et al. (1991) Second primary cancer following Hodgkin's disease: Updated results of an Italian multicentric study J Clin Oncol, 9, pp. 432-437.